Into the future: Prevention of diabetes

Contributions to Nephrology

Volumn 170, Issue , 2011, Pages 256-263

  Bogaert, Yolanda E ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; BARIATRIC SURGERY; DRUG EFFECT; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WEIGHT REDUCTION;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; HUMANS; LIFE STYLE; RENIN-ANGIOTENSIN SYSTEM; WEIGHT LOSS;

EID: 84925941638     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000325781     Document Type: Article

References (20)

1. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19. (Pubitemid 36237741)
2. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350. (Pubitemid 32378388)
3. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29:2102-2107. (Pubitemid 44871194)
4. Kosaka K, Noda M, Kuzuya T: Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males. Diabetes Res Clin Pract 2005;67:152-162. (Pubitemid 40093025)
5. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP): The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49: 289-297. (Pubitemid 43185397)
6. Carter P, Gray LJ, Troughton J, Khunti K, Davies MJ: Fruit and vegetable intake and incidence of type 2 diabetes mellitus: Systematic review and meta-analysis. BMJ 2010; 341:c4229.
7. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693.
8. Dixon JB, Dixon AF, O'Brien PE: Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabet Med 2003;20:127-134. (Pubitemid 36269654)
9. Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, Ferrannini E: Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: Role of insulin sensitivity and beta cell function. Diabetologia 2006;49: 2136-2143. (Pubitemid 44168482)
10. Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO, Klein S, Abumrad NN: Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139: 448-455.
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403. (Pubitemid 34437694)
12. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: The STOPNIDDM randomised trial. Lancet 2002;359: 2072-2077. (Pubitemid 34680970)
13. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: A randomized, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-1614.
14. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 2006;368: 1096-1105.
15. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ: Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): A doubleblind randomized controlled study. Lancet 2010;376:103-111.
16. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562. (Pubitemid 44550032)
17. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-1490.
18. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME, NN8022-1807 Study Group: Effects of liraglutide in the treatment of obesity: A randomised, doubleblind, placebo-controlled study. Lancet 2009; 374:1606-1616.
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393. (Pubitemid 36159355)
20. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87: 4-14.